Phase II-III

Charting the course for faster and easier Phase II-III

Your clinical development has shown strong potential so far and the end goal of launching to market inches closer. As you enter Phases IIb and III, enhanced scrutiny of your fledgling product will inevitably throw up various challenges.

This is the time when your decision to partner with us proves most fruitful, as our experienced consultants dig deep into their extensive knowledge and deploy the resources that fit your needs – sharp strategies to steady the course, clinical logistics to implement trials swiftly and the regulatory knowledge to avoid the obstacles which could lead to extra risks, delays, and costs. 

Because our Regulatory & Access experts are plugged into the realities of clinical development, their technical insights – regulatory, pricing and reimbursement, patient access – are geared towards more practical, actionable solutions that can be integrated into your Parexel development programs. It’s the difference between ideas that are nice in theory, and those that are effective in practice.

No matter what this phase throws at you, we’ll be at your side, as invested in and excited by your potential new treatment as you are.

2020 Pediatric Perceptions & Insights Study

View Now

Making rare disease drug development personal

View Now

Bringing clinical trials to patients with the decentralized model

View Now

Genomics & biomarkers: Answers in the blood

Watch Now

Decentralized Clinical Trials and Patient Needs

Watch Now

Using sensor technology to deploy Decentralized Clinical Trials and improve patient care

Read Now

Innnovating for the Future of Drug Development

View Now

Parexel FSP Culture Map

View Now

Rise of FSP Outsourcing article

View Now

COVID-19 The Great Decentralized Clinical Trials Accelerator

View Now

We are always available for a conversation.

Submitting...

Communication Preference

Communication Preference